^
    Back
    Association details:
    Biomarker:MDM2 amplification
    Cancer:Glioblastoma
    Drug:brigimadlin (BI 907828) (MDM2-p53 antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Mol Cancer Ther
    Title:

    Delivery versus potency in treating brain tumors: BI-907828, a MDM2-p53 antagonist with limited BBB penetration but significant in vivo efficacy in glioblastoma

    Published date:
    10/13/2023
    Excerpt:
    MDM2-amplified cells are highly sensitive to BI-907828, with an effective unbound concentration of 0.1 nM.
    DOI:
    10.1158/1535-7163.MCT-23-0217